Ensil Canada is Inviting Publicly Traded Companies to Partner in the Development of Flexusys, an Exciting Medical Device That Will be Used to Predict Cardiac Arrest in Patients

    MARKHAM, ON, March 10, 2014 /24-7PressRelease/ -- Ensil's team of researchers, scientists and engineers have ventured into developing a new medical device for those at risk of cardiac arrest.

This device, known as Flexusys, would utilize proprietary patented technologies and algorithms developed by Ensil Canada to detect, monitor and alert the patient and emergency health care providers of an imminent cardiac arrest.

Unlike other devices that are implanted subcutaneously, Ensil's device is a wearable technology. It removes the need for complicated medical procedures, thus reducing health risks and costs to patients, governments and insurance companies.

Farsad Kiani, President of Ensil Canada, commented, "According to the Heart and Stroke Foundation of Canada, there is one heart attack every 7 minutes in Canada and up to 40,000 cardiac arrests each year. That is one cardiac arrest every 12 minutes. In addition, there are an estimated 350,000 Canadians living with atrial fibrillation. These numbers are expected to increase with the growth of Canada's aging population also in US. Each year, nearly 360,000 emergency medical services are assessed as result of cardiac arrests conditions. The Flexusys medical device will use proprietary technology to reduce the number of deaths from cardiac arrest by monitoring various medical indicators in real-time and alerting the patient of the possibility of an impending medical emergency."

Ensil Canada is extending an open invitation to publicly traded companies to partner with Ensil on this exciting initiative by contributing resources, as well as their development, clinical trial and marketing expertise, with the goal of reducing development time to bring this important device to market in a fast and efficient manner.

Ensil Canada is a member of the Ensil group of companies (www.ensil.com), focused on enhancing mission-critical technologies in the areas of Aerospace, Defence and Medical Diagnostic Equipment. Ensil's Research and Development division's mission is to develop new technologies or improve existing technologies, leveraging its in-house aerospace, defence and medical technology expertise, research and resources.

For over 30 years, a fundamental belief in "Innovation beyond Imagination" has been part of Ensil's corporate culture. Since its inception, the company has built its brand in the North American Aerospace and Defence industries as a boutique engineering and R&D technology.

# # #